Gene editing with CRISPR/Cas methodology and thyroid cancer: where are we? (2022)
Fuziwara, Cesar Seigi 
; Mello, Diego Claro de ; Kimura, Edna Teruko
Subjects: BIOLOGIA CELULAR, NEOPLASIAS DA TIREOIDE, CÉLULAS CULTIVADAS DE TUMOR, GENES, GENES, GENOMAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FUZIWARA, Cesar Seigi e MELLO, Diego Claro de e KIMURA, Edna Teruko. Gene editing with CRISPR/Cas methodology and thyroid cancer: where are we?. Cancers, v. 14, n. 3, p. 1-21, 2022Tradução . . Disponível em: https://doi.org/10.3390/cancers14030844. Acesso em: 05 nov. 2024.APA
Fuziwara, C. S., Mello, D. C. de, & Kimura, E. T. (2022). Gene editing with CRISPR/Cas methodology and thyroid cancer: where are we? Cancers, 14( 3), 1-21. doi:10.3390/cancers14030844NLM
Fuziwara CS, Mello DC de, Kimura ET. Gene editing with CRISPR/Cas methodology and thyroid cancer: where are we? [Internet]. Cancers. 2022 ; 14( 3): 1-21.[citado 2024 nov. 05 ] Available from: https://doi.org/10.3390/cancers14030844Vancouver
Fuziwara CS, Mello DC de, Kimura ET. Gene editing with CRISPR/Cas methodology and thyroid cancer: where are we? [Internet]. Cancers. 2022 ; 14( 3): 1-21.[citado 2024 nov. 05 ] Available from: https://doi.org/10.3390/cancers14030844
